Oct 20 2009
Cancer has quickly become one of the deadliest diseases, causing well over 13% of all human deaths. Cancer rates could further increase by 50% to 15 million new cases in the year 2020, according to the World Cancer Report, the most comprehensive global examination of the disease to date.
Due to this emerging need for cancer detection medical devices, new and innovative technologies are bound to step foot within the coming years, in what could potentially be one of the biggest markets of our era.
Xtend Medical (PINK:XMDC) is set to partner up with BioHarp Korea, a division of Uni Bio-Tech, Inc, a Seoul, Korea based developer and manufacturer of medical imaging devices. Under the terms of the merger, BioHarp Korea will transfer all patents, software, assets, and proprietary information relating to the BioHarp Nano Sensor imaging device.
Upon completion of the merger, the combined company will apply for a name change from XTend Medical to BioHarp Uni, US, and will effectuate a new trading symbol and cusip number. The merger is expected to be completed 30 to 60 days post the October 1st, 2009 press release. BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. It is an hand-held, lightweight, portable, and affordable device which has tested for 100% no-false positives, and 95.9% cancer positive .
With the U.S. National Science Foundation predicting that the market for nanotechnology, or products containing nanotechnology, will reach $1 trillion in 10 to 15 years — XTend, and other medical nanotechnology devices should begin to receive a lot more praise, including the likes of NASA, which has already developed a nanotechnology-based biosensor which helps detect biohazards. “If we realize our sales and marketing goals and hit our projected revenues based on the current inquiries we’ve received, the company’s market cap will be substantial,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.
About XTend Medical
XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.
The full special report on the company appears today at www.stockshaven.com/xtend-medical-set-to-redefine-cancer-detecti ..